NLS Ilya Pharma

Ilya Pharma has announced that Oskar Lund has been appointed Chief Financial Officer. Lund joins at a pivotal stage in the company’s development as it eyes a potential IPO following recent positive results from the first in human (FIH) trial of its lead candidate ILP100 for treating difficult and chronic wounds, the company states. “Oskar […]

The company has received approval from the Swedish Medical Product Agency and Swedish Ethical Review Authority to initiate a Phase II clinical study of its ILP100 gene therapy for the treatment of difficult diabetic wounds. ILP100h has recently been assigned the INN name emilimogene sigulactibac by the WHO and represents a new-in-class drug candidate, engineering […]

The CEO of Ilya Pharma, Evelina Vågesjö, is listed for Advanced therapies by the The Medicine Maker. She is on the list together with the former Head of Cell- and Gene therapies at Novartis bringing the first CAR T cell therapy to market and the recent Nobel Laureates and users of the CRISPER technology. Read […]

Ilya Pharma has announced that the European Patent Office has issued the company European Patent titled “Methods for Wound Healing”. The patent covers the use of the lactic acid bacteria Lactobacillus reuteri, which have been transformed with a plasmid capable of expressing a wound healing protein selected from CXCL12, CXCL17 and Ym1 to heal cutaneous […]

Ilya Pharma has announced positive results from an extensive Phase I trial of its lead candidate ILP100 for the treatment of difficult and chronic wounds. ILP100 is the first drug candidate based on genetically engineered Lactobacillus to be approved to enter human trials and has required new innovative approaches to CMC, bioassays and protocol development. […]

What began as a project for Evelina Vågesjö’s doctoral thesis grew into groundbreaking drug candidates and delivery methods, followed not long afterwards, by a clinical-stage biopharmaceutical company.